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Abstract
In 1994, combined active and passive screening reported 1469 cases from the historic
Gambian Human African Trypanosomiasis (gHAT) foci of West Nile, Uganda. Since 2011
systematic active screening has stopped and there has been reliance on passive screen-
ing. During 2014, passive screening alone detected just nine cases. In the same year a
tsetse control intervention was expanded to cover the main gHAT foci in West Nile to cur-
tail transmission of gHAT contributing to the elimination of gHAT as a public health prob-
lem in the area. It is known that sole reliance on passive screening is slow to detect cases
and can underestimate the actual true number. We therefore undertook an active screen-
ing programme designed to test the efficacy of these interventions against gHAT transmis-
sion and clarify disease status. Screening was conducted in 28 randomly selected villages
throughout the study area, aiming to sample all residents. Whole blood from 10,963 partic-
ipants was analysed using CATT and 97 CATT suspects (0.9%) were evaluated with
microscopy and trypanolysis. No confirmed cases were found providing evidence that the
gHAT prevention programmes in West Nile have been effective. Results confirm gHAT
prevalence in the study area of West Nile is below the elimination threshold (1 new case /
10,000 population), making elimination on course across this study area if status is main-
tained. The findings of this study can be used to guide future HAT and tsetse management
in other gHAT foci, where reduced caseloads necessitate a shift from active to passive
screening.
Author summary
The number of gHAT cases across West Nile, Uganda has declined in the last 20 years.
This decline is due to the impact of programmes of active and passive case detection and
treatment which have recently been combined with tsetse control operations (post
2011). We carried out an active survey of gHAT to evaluate the prevalence in areas
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where vector control has been introduced. Our results confirm that the overall preva-
lence of gHAT is below 1 case per 10,000 people at risk in the historical foci and shows
that results from passive screening are providing an accurate picture of gHAT preva-
lence in the area.
Introduction
Human African Trypanosomiasis (HAT) is caused by species of Trypanosoma brucei s.l.
transmitted by tsetse flies, with case fatality rates believed to be close to 100% [1, 2]. In East
and Southern Africa Trypanosoma brucei rhodesiense causes Rhodesian HAT (rHAT), an
acute and zoonotic form of the disease. In Central and West Africa Trypanosoma brucei gam-
biense causes Gambian HAT (gHAT), the chronic form of disease and is generally considered
an anthroponosis [3, 4]. gHAT has been targeted for elimination globally by reducing inci-
dence to less than 1 new case per 10,000 people at risk in 90% of foci, alongside a global total
burden of less than 2000 cases by 2020 [5]. In 2017, one of the metrics to assess elimination
as a public health problem was revised as ‘total area at risk reporting � 1 case per 10,000 peo-
ple per year’ [6]. The only country where both forms of the disease occur is Uganda with
gHAT present in the north west [7] and rHAT in central and south-eastern parts of the coun-
try [8]. Unregulated movement of untreated cattle risk rHAT extending its distribution [9].
Control of gHAT classically relied upon medical surveillance involving either active or pas-
sive screening of the population followed by treatment of detected cases. In practice, when
prevalence decreases, exhaustive active screening by mobile teams is progressively replaced
by passive screening with diagnosis of patients presenting at local health centres [10]. Prompt
and correct diagnosis of HAT requires specialist diagnostics, facilities and skilled staff which
are frequently not present at most health centres in remote rural areas. Consequently, misdi-
agnosis and under-reporting of HAT cases by passive screening is an acknowledged problem
[11–14].
In Uganda, the annual number of reported gHAT cases declined from 2066 in 1990 to 1469
cases in 1994 and on to just nine cases in 2014 [15]. The driver behind this decline being the
large active and passive screening programme by Ugandan National Sleeping Sickness Pro-
gramme and Me´decins Sans Frontières (MSF) France between 1987 and 2002 [16]. As case
numbers declined surveillance shifted from large-scale active screening to passive screening. It
is plausible that the current low case numbers could be an underestimate due to less effective
screening. The last large-scale active screening in West Nile was undertaken by MSF Spain and
the Ministry of Health (MoH) supported by WHO in 2010 and 2011. A total of 74,254 people
were screened with 22 people diagnosed positive and treated for gHAT at an overall prevalence
of 0.029% [17]. All parasitological confirmed cases reported since then have been detected at
MoH facilities by passive screening only.
As a contribution to eliminate gHAT as a public health problem in Uganda, tsetse control
operations have gradually been expanding in West Nile since 2011. This involves the deploy-
ment of insecticide treated Tiny Targets [18] throughout the traditional foci of gHAT managed
by the Co-ordinating Office for the Control of Trypanosomiasis in Uganda (COCTU) sup-
ported by Liverpool School of Tropical Medicine (LSTM). To evaluate the status of gHAT in
areas where Tiny Targets have been deployed, an active screening survey for gHAT has been
conducted in the historical gHAT foci of Arua, Maracha, Koboko and Yumbe. Areas of Arua
and Maracha have had the Tiny Target tsetse control project since 2011, while in Koboko and
Yumbe Tiny Targets were introduced in 2014.
Gambian human African trypanosomiasis in North West Uganda
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007550 August 14, 2019 2 / 15
Materials and methods
Ethical statement
Sampling activities were conducted in accordance with the Helsinki Declaration. This study
was designed in collaboration between LSTM, COCTU, and the National Sleeping Sickness
Control Program, Ministry of Health (MoH). Ugandan National Council of Science and Tech-
nology granted formal ethical approval (protocol number: HS1749). All samples were collected
using the existing national framework for trypanosomiasis screening, employing laboratory
technicians from Omugo Health Centre (one of the principal gHAT diagnostic facilities in
West Nile region). Care was taken to minimise changes in the techniques used for this study
from the standard operating procedure already familiar to the health team.
Description of study area
This study investigated the historical gHAT foci situated north east of Arua town. Between
2000 and 2012 the study site generated 1448 gHAT cases out of the national total of 3940. The
foci extend from 3˚06’17.32” to 3˚37’10.53” latitude, and 30˚56’23.28” to 31˚25’57.65” longi-
tude and encompasses areas of Arua, Maracha, Koboko and Yumbe districts. This study area
hosts vector control operations through deployment of Tiny Targets. In Arua and Maracha
districts control started at scale in 2012 followed by Koboko and Yumbe in late 2014 [18].
HAT cases reported to WHO from each of these areas during the period 2000–2012 were 689
in Arua and Maracha and 759 from Koboko and Yumbe. These two regions form the sub areas
of this survey. The population is largely rural, practising small-scale crop farming focussed on
food and tobacco. The rivers in the study area include the Enyau, Kochi and Ore along with
their smaller tributaries. These rivers support the typical riverine habitat suitable for Glossina
fuscipes fuscipes, the principal T. b. gambiense vector in this area [18, 19].
Human medical survey
Study design. This study aimed to detect any difference in the number of gHAT cases
from areas where vector control had been previously established (Arua and Maracha) and
were the technology had very recently become introduced (Koboko and Yumbe). The study is
designed as a single stage cluster sampling operated within the defined study areas. Sample site
villages within the gHAT focus were selected at random and all residents of selected village
clusters were invited for inclusion with an aim to sample each person. To calculate the number
of village clusters required, village population figures were obtained from local government
officials holding the position of sub-county leader (the information was not available through
centralised governmental organisations). Villages had an average of 510 people (range: 217 to
917). Prevalence data from active gHAT screening by MSF in 2010 to 2011 was used to calcu-
late the sample size required in each of the two areas, outlined as follows. Prevalence in Arua
and Maracha districts was 0.036% (12/30,726). Koboko and Yumbe was 0.023% (10/43,528).
Sample size calculations were completed using Winpepi [20] establishing the number of vil-
lages (clusters) needed in both areas. Calculations were made with a confidence interval of
95% and an acceptable difference of 0.08%. Based on this sample size calculation the number
of village clusters needed to be sampled was 17 villages between Arua and Maracha (tsetse con-
trol introduced at scale in 2011), and 10 villages across Koboko and Yumbe (tsetse control
introduced late 2014). Given the average village population is 510 people the anticipated popu-
lation of 27 sampled villages was 13,770.
Selection of sampling villages utilised a government collated list of Ugandan villages (com-
piled by Ugandan Bureau of Statistics during 2010). This list was filtered to include all villages
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within the gHAT focus as defined by WHO derived data on HAT cases since 2005. This gener-
ated data of all known villages located in parishes that had been declared as the home of gHAT
cases. The list for Arua and Maracha comprised of 449 villages, while the list for Koboko and
Yumbe produced 443 villages. Final selection was made by assigning each village a number in
numeric sequence and used the random number generator of WinPepi to select numbers
within the range of the village list. This process was done twice for the respective sub-areas.
After selection of the survey villages, a further ten villages were chosen at random (five for
each of the two sub-areas ready to be used if severe problems were encountered in surveying
the villages originally selected).
Sample protocol. Sampling operations ran between June and August 2015. Each village
was visited for sensitisation 48 hours before screening in which village chairpersons were
informed about the risk posed by gHAT, the method of sampling, that sampling was free and
every member of the village was invited to attend. Sampling was carried out between 09:00 and
17:00 h to ensure the team’s safety. Geo-referencing was carried out using Garmin eTrex 20 at
each sample site. Participants were given comprehensive details in appropriate languages
regarding the sampling procedure and requested to sign an informed consent form. Each par-
ticipant was then designated a unique identification number to enable tracing of individuals
and their age, gender and name of the home village was recorded. Village chairpersons pro-
vided the number of residents in their village and worked to identify persons who were from
outside of their village. Upon identification, these external participants were still tested but
were recorded as not from the village. Fig 1 depicts the diagnostic algorithm used for this sur-
vey, indicating the actions for a positive and negative result at each stage of investigation.
Diagnosis of T. b. gambiense was conducted following a three stage protocol consisting of
initial screening, parasitological confirmation and finally disease staging of any cases [22]. For
initial screening Card Agglutination Trypanosomiasis Tests (CATT) were used. WHO in coor-
dination with the Ugandan National Sleeping Sickness Control Program provided the CATT
used in this survey. Each participant was tested using the CATT protocol on whole blood
(CATT-WB) [10, 22]. If the CATT-WB test was negative, participants were informed and free
to leave. If a test displayed agglutination, samples were advanced to further CATT tests over a
series of dilutions; 1:4, 1:8 and 1:16 and microscopic examination took place. Dilution of
plasma increases the specificity; agglutination at greater dilution gives an increased suspicion
that the participant is positive for gHAT [21, 23]. Participants with a positive CATT-WB result
were asked if they had previously had HAT and if so, when (for case history clarification).
Confirmation of gHAT infection was done in accordance with the Ugandan Government
MoH guidelines for diagnosis using microscopic examination. The low parasitemia of T. b.
gambiense renders unprocessed blood analysis unlikely to find trypanosomes [22]. Following
MoH guidelines, we used the Capillary Tube Centrifugation (CTC) technique [24], centrifug-
ing samples at 3000 rpm for five minutes to concentrate trypanosomes within the buffy layer.
From each CATT-WB suspect, three capillary tubes were analysed with Leica light micro-
scopes using 40x magnification oil immersion lenses. If suspects (i.e., those with agglutination
from CATT) were found microscopically negative during active screening, they were referred
for follow up after three months at a regional health centre for final confirmation. If the suspect
had palpable cervical lymph nodes a sample was aspirated and examined microscopically.
Each participant with CATT-WB agglutination had a fourth capillary tube of blood col-
lected from the same puncture wound. Blood was applied directly to Whatman filter paper
and dried for one hour out of direct sunlight. Samples were then sealed with silica desiccant in
individual plastic sachets and stored at 4˚C before being dispatched to the WHO collaborating
centre in CIRDES laboratory in Bobo Dioulasso, Burkina Faso for analysis by the trypanolysis
test [25, 26].
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Cartography
Mapping of the study area was carried out using a combination of open source GIS shapefiles
and data from the WHO. National boundaries, rivers and water bodies were obtained from
DIVA-GIS [27]. Human population data has been obtained from the Centre for International
Earth Science Information Network [28]. Data from the HAT Atlas, provided by WHO, were
used to produce a map of the gridded density of HAT cases across the study area. This data
was used to show density of gHAT cases based upon reported origin position of each case
within cells of a 1km2 grid covering the West Nile region. All GIS processing has been con-
ducted using QGIS [29].
Results
One of the randomly selected reserve sample sites was added after one original sample site pre-
sented a turnout of less than 25% of the population (as provided by village leaders). Therefore,
a total of 28 villages were sampled comprising all 27 of the originally selected village sites and a
single reserve village. Samples were collected from 10,963 people at 28 village sample sites
shown in Fig 2. No sample site was more than 8km from the home village of a gHAT case
recorded in the previous decade. The total population of the 28 sample villages was estimated
by village leaders as 14,225 inhabitants, giving an overall sample coverage of 77.1%. Of the
10,963 that were screened, 10,500 were residents of the selected sampling villages and 463 were
non-residents. Thus, the attendance rate from the selected villages was 73.8%.
Demographics of the sampled population
The sampled population comprised 51.9% females and 48.1% males (Fig 3) and the age distri-
bution was in general accordance with the population composition of Uganda, with more
Fig 1. Decision tree for each step of the gHAT sampling, adapted from Simarro et al [21].
https://doi.org/10.1371/journal.pntd.0007550.g001
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young than old. Direct comparison between results from this study and the United Nations’
collated population for Uganda places the UN’s curve from young to old as being far more
gradual [30, 31] than our data (Fig 3).
CATT findings
Initial CATT-WB screening showed agglutination for 0.88% of people screened (97/10963, CI:
0.7–1.1) (Table 1). Following the diagnostic algorithm of these initial positives, 59.2% (61/97,
CI: 52.5–72.5) displayed CATT agglutination at 1:4 dilution, 26.2% (27/97, CI: 19.2–37.9) at
1:8 dilution and 13.6% (14/97 CI: 8.1–23.0) at 1:16 dilution. Results of CATT-WB conducted
in the sub-areas shows no significant difference (p = 0.8521) between Arua and Maracha (69/
7647) and Koboko and Yumbe (28/3316).
Sixty-seven of the 97 CATT-WB suspects were from the selected study cluster villages. The
remaining 30 CATT-WB suspects were from other villages (total number of identified attend-
ees from unselected villages was 463). From selected sample villages, 0.64% were CATT-WB
suspects (67/10500 CI: 0.54–0.73). CATT-WB suspects from non-selected villages represent
6.48% (CI: 4.4–9.1). Number of CATT-WB per sample site is shown in Fig 4.
Microscopy
None of the screened participants that were serologically positive by CATT on whole blood (0/
97, CI: 0–3.7) were confirmed positive using CTC microscopic analysis to identify trypano-
somes. Only one CATT-WB suspect had palpable lymph nodes (lymph was examined micro-
scopically and found negative). All CATT-WB suspects were given appointments for follow up
Fig 2. Location of randomly selected sample sites, related to human population density and the origins of past HAT cases.
https://doi.org/10.1371/journal.pntd.0007550.g002
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screening after three months and 79 of the 97 suspects attended (76.6%), with none confirmed
positive by microscopy. As these individuals had previously been identified as CATT suspects,
they were not re-examined by CATT during follow up. As there were no cases diagnosed by
microscopy it is not possible to compare the two sub areas of this study.
Trypanolysis
Analysis of blood indicated that three of 97 undiluted (CI: 0.6–9.0) CATT-WB suspects had
previously been infected with T. b. gambiense. The original sampling locations of these three
individuals is plotted in Fig 4. All three were from Arua district in neighbouring locations and
while it appears from the map that two are from the same village, records show one was from a
neighbouring non-selected village.
One trypanolysis suspect had agglutination registered for all dilutions of CATT (1:4, 1:8,
1:16). Two only had agglutination on the whole blood test, no agglutination in dilutions. None
had palpable lymph nodes. The individual with consistent agglutination at all dilutions is a
past HAT patient who was treated 15 years previously. Geographic assessment of home village
locations of the three trypanolysis positive suspects shows they were within 0.5km of the
Enyau river system, a documented tsetse habitat [18]. There is no significant difference in the
findings of trypanolysis between the sub areas (p = 0.5545), 3/66 from Arua and Maracha and
0/28 from Koboko and Yumbe.
Past HAT case history
Five of the CATT-WB suspects have previously been HAT cases and while all had received
treatment, their staging status is unclear from records. Four were from selected survey villages
and one had come from an un-selected village. WHO’s HAT case data from 2000 and 2012
shows the same villages sampled in this study had produced 18 HAT cases. Four of the 18
(22.2%) were identified and resampled during this screening. Given the area that village
Fig 3. Demographic of the screened population as a percentage of the total screened population (shown on the
left, a) and UN derived national demographic data for Uganda (shown on the right, b).
https://doi.org/10.1371/journal.pntd.0007550.g003
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clusters were selected from has reported 1448 gHAT cases in 892 villages, there was 1430 cases
reported to the WHO from the 864 unselected villages.
Discussion
The absence of confirmed cases in this active screening study supports the conclusion from
previous passive screening in West Nile that gHAT transmission in the area is now at a very
low level and within the threshold for achieving elimination. The lack of cases makes statistical
comparisons of the sub areas with different dates of vector control inappropriate. As a result,
the findings are discussed as a single area.
Sampling achieved an average of 73.8% coverage of village populations, comparable to simi-
lar surveys [32, 33]. Eleven villages have a sample coverage of over 100%, highlighting the
Table 1. Results of active screening shown by sample (village) site, combined totals included at bottom.
District Village Name Total population
(reported by
village chief)
Villagers
sampled
Identified
non-villagers
Percent
sampled
CATT
whole
blood
CATT
1:4
CATT
1:8
CATT
1:16
CTC
microscopy
positive
Trypanolysis
positives
Arua and
Maracha
CHAKAYI 874 252 0 28.83 1 1 0 0 0 0
EJAVU 166 165 10 99.40 0 0 0 0 0 0
KIDIA 153 153 23 100.00 1 1 0 0 0 0
AMIA 249 249 13 100.00 1 1 0 0 0 0
ODOA 872 215 0 24.66 3 0 0 0 0 1
ILLY HILL 1028 534 1 51.95 5 4 2 1 0 0
MGBAFEA 704 477 1 67.76 2 1 1 0 0 0
ARUMAZE 619 619 9 100.00 3 2 0 0 0 0
AZAAPI 495 495 214 100.00 4 3 3 2 0 0
DUKU 348 301 0 86.49 6 0 0 0 0 1
KOMENDAKU 964 782 4 81.12 7 7 3 2 0 0
AYIVU 495 495 52 100.00 1 0 0 0 0 0
JOYIA 258 234 2 90.70 2 0 0 0 0 0
KANGAYI 469 410 1 87.42 1 1 1 0 0 0
ROBU 669 560 1 83.71 1 1 1 1 0 0
BURA OPIDRI 700 515 3 73.57 1 0 0 0 0 0
ANDELIZO 500 500 16 100.00 6 5 2 1 0 0
AJULEPI 386 338 3 87.56 1 1 1 1 0 0
Koboko
and
Yumbe
LUSUGO 389 203 3 52.19 0 0 0 0 0 0
LWANGA 174 174 32 100.00 0 0 0 0 0 0
TUKALIRI 590 438 5 74.24 3 3 0 0 0 0
MONDRUGORO 212 212 2 100.00 0 0 0 0 0 0
DEMGBELENGA 1467 787 0 53.65 0 0 0 0 0 0
YAMIRO 306 299 2 97.71 2 2 1 0 0 0
IJIGO 169 154 0 91.12 2 0 0 0 0 0
EWANYATI 243 213 1 87.65 7 4 2 1 0 0
KITOLI 167 167 19 100.00 1 1 0 0 0 0
ANAFIYO 559 559 46 100.00 6 5 2 1 0 0
Cluster village population
total
14,225 10,500 463 73.81 67 43 19 10 0 2
Non-residents of cluster N/A 463 N/A N/A 30 18 8 4 0 1
Combined total 14,225 10,963 N/A 77.07 97 61 27 14 0 3
https://doi.org/10.1371/journal.pntd.0007550.t001
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Fig 4. Numbers of CATT on whole blood suspects and number of trypanolysis positives found at each sample point.
https://doi.org/10.1371/journal.pntd.0007550.g004
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reality of unreliable population estimates compounded by people from outside the sample site
attending for screening. As an example, Azaapi sample site had attendance by 214 people from
outside the cluster village. This was driven by Azaapi holding both a school and large church
resulting in information about sampling spreading to neighbouring villages. In 2015 the Ugan-
dan population was estimated as having much more gradual gradient change from the young
to the elderly compared to our data (Fig 3) suggesting our sample may have a disproportionate
number of children [30]. As such there was a higher than expected attendance by children
which can be attributed to youngsters being encouraged to attend by guardians or school lead-
ers. Data shows a lower number of males reporting for sampling than females, especially
between the ages of 20 and 59. This male population may be at a relatively high risk of HAT
infection due to increased exposure to tsetse during their working day. Working commitments
could also explain their abstention from screening. Partial absence of working age males has
been noted in similar medical surveys [34]. Fears inherent in the population have mostly been
negated through sensitisation and understanding [32]. In our study extensive sensitisation
efforts were made prior to the sampling to encourage population attendance, which exceeded
70%, highlighting its value.
A higher proportion of people from outside selected villages were identified by CATT-WB
than those from selected sample cluster villages. Possible contributing factors to this result are
people being aware of exposure to tsetse bites or previously been diagnosed as a historical
HAT case thereby willing to attend a diagnostic sampling or clinic for their own peace of
mind. Investigation into the home villages of these participants shows they were all from
within the overall study area centred around historic gHAT foci with the majority coming
from the villages immediately neighbouring the randomly selected sample site. This difference
in CATT-WB agglutination between the subgroups of the sample suggests that given opportu-
nity, people at high risk of HAT exposure are likely to seek out screening. This may be a reflec-
tion of the high levels of awareness of gHAT in these communities [19].
Microscopic examination of the 97 CATT-WB suspects yielded no confirmation of HAT
cases during active screening or follow up. Trypanolysis analysis confirmed three suspects as
having immunological evidence of T. b. gambiense infection. These three individuals were all
residing near one another. Home locations are all within 500m of a known tsetse habitat,
placing them at high risk of being bitten by tsetse that could potentially be infected with T. b.
gambiense. One of the two immunologic positive individuals that were only identified by
CATT on whole blood (i.e., with no agglutination generated from serial dilution) had no
HAT case history. As this 27-year-old male has no HAT case history it is possible he is an
untreated survivor of the disease and either a potential reservoir or a spontaneous cure [25],
meriting follow-ups in the future. The second trypanolysis suspect [a 70-year-old male] only
had agglutination on CATT whole blood test with no agglutination on dilution. This individ-
ual had been diagnosed and treated for gHAT ten years earlier. The third trypanolysis posi-
tive [a 50-year-old female] had agglutination through all dilution ratios despite 15 years
having elapsed since treatment for HAT. None of these three individuals was found positive
by microscopy during follow up at Omugo health centre. This supports existing work indi-
cating the potential weaknesses in relying solely on CTC microscopy which can miss low
parasitaemias [35], particularly in seemingly healthy carriers. These immunologic findings
in the absence of confirmation by microscopic analysis of blood could be self-cures or
healthy carriers with very low parasitemia in the blood and lymphatic system, undetected by
CTC microscopy. Another hypothesis is that the individual has trypanosomes persisting in
skin or fat deposits and therefore presents as an immunologic suspect but microscopic nega-
tive [36, 37]. These parasites have the potential to remain viable and conceivably form a res-
ervoir for transmission to feeding tsetse.
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Implications to gHAT control policy
Reduction of HAT cases in West Nile has been driven by intensive active and passive medical
screening and treatment of infected people between the years of 1987 and 2002 [16]. Recently,
as case numbers have dropped, active screening has been scaled back in conjunction with rein-
forcement of passive screening. This shift has been accompanied by establishment of an effec-
tive tsetse control programme which has reduced tsetse apparent densities by over 80% [18].
Our results indicate that the previous combined active and passive screening strategy had a
successful impact to reduce HAT cases, which has recently been maintained through strategic
passive screening. While tsetse control has not produced the low prevalence of gHAT
observed, it will have reduced the risk of undiagnosed infected individuals being fed upon and
parasite becoming transmitted [38]. While the sampling turnout for this study (~72%) is con-
sidered satisfactory, it highlights the difficulties and risk of relying only on screening and treat-
ment for controlling HAT. This is particularly pertinent in less accessible areas where repeated
team visits are impossible, leaving many individuals unscreened. The study was focussed on
one of the most active foci of gHAT in Uganda and findings have relevance to other foci since
all Ugandan gHAT foci are now benefiting from combined reinforced passive screening and
tsetse control.
Since this study concluded, new cases of gHAT from Uganda have remained low; 4 cases in
2015, 4 in 2016 and 2 in 2017 (both of which were in South Sudanese refugees and not Ugan-
dan nationals). Deterioration of security in South Sudan has resulted in an influx of>1 million
refugees entering West Nile [39]. This is highly relevant to this study and the Ugandan HAT
situation. While effort has been invested and gains made against HAT in Uganda, the WHO
HAT atlas [40, 41] shows that there are foci of gHAT in neighbouring areas of South Sudan
[15]. Large numbers of people have fled these areas and have settled in refugee camps in vari-
ous districts of West Nile. Consequently, there is urgent need for raising awareness about
HAT in the refugee population and screening for gHAT in refugee camps. Alongside this is a
necessity for tsetse control, which focusses on tsetse habitat around the camps and protects the
South Sudanese refugees and Ugandan communities from re-emergence of gHAT.
This study demonstrates that the transition from active screening to enhanced passive
screening has been successful in providing an accurate representation of gHAT prevalence.
The authors therefore recommend that enhanced passive screening should form the basis for
control in areas where prevalence is low (be that naturally or having been reduced by active
screening operations). In regions of high prevalence active screening still has an important
role but should be replaced by enhanced passive screening (as used in West Nile [42]) once a
low prevalence has been achieved. As an example, when active screening operations find fewer
than five cases per 10,000 people screened, priority can shift to reinforced passive screening
combined with focussed active screening at home locations of new cases. Specific thresholds
for prioritising reinforced passive screening should be decided by the national MoH with guid-
ance from WHO. This will reduce the burden of cost on the healthcare system.
Alongside screening programmes recent advances in vector control and chemotherapy
show promising contributions to gHAT control [42]. Considerations should be taken to imple-
ment their usage in future operations as outlined below.
In Uganda, gHAT elimination as a public health problem was attained on the back of the
work done prior to the introduction of large-scale vector control. No cases have occurred in
areas where Tiny Targets have been deployed. This provides early indication that vector con-
trol has helped to maintain incidence at a very low level through directly interrupting trans-
mission. Tsetse control provides a necessary means of continuing the suppression of HAT
transmission [38, 43] by minimising the risk posed by infected individuals who miss medical
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screening and could pass on infection. The consistent stand out risk group in this and other
studies is the working age males who represent low attendance figures in screening operations.
In addition, tsetse control is especially pertinent if trypanosomes can survive undetected, for
example in the skin and fat deposits remaining accessible to feeding tsetse, but are elusive to
detection by microscopic analysis. Vector control will also negate any risk posed by potentially
viable animal reservoir infections of T. b. gambiense [44].
Advances in orally-administered drugs for gHAT are highly promising since they offer the
prospect of an easier and safer treatment for HAT cases with a simpler treatment regimen [45]
thereby reducing the burden on health care systems. Treatment options such as nifurtimox-
eflornithine combination therapy remain valuable particularly as second line treatment against
second stage gHAT. Fexinidazole has been proven capable of diffusing outside of blood and
lymph system, into both fat and skin [46]. This presents exciting scope for eliminating trans-
mission from any potential asymptomatic cases through treatment of highly reactive serologi-
cal or trypanolysis suspects (providing test results are relayed from the lab to local health
teams to follow up).
Mathematical models [38, 47] predict that combination of tsetse suppression with medical
screening intervention is needed to ensure that WHO’s target of eliminating gHAT as a public
health problem (i.e., < 1 case per 10,000 people at risk by 2020) is achieved globally. In
Uganda, the health care structure is well developed aiding the success of passive surveillance
[48] which permitted the possibility of effective control based largely on active and passive
screening. The strategy of reducing incidence through vector control will be important as an
accompaniment to medical surveys [43], particularly in regions of gHAT endemicity that lack
health centres capable of accomplishing gHAT passive screening.
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